Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 12,101–12,200 of 15,747
The Risk Management of COVID-19: Lessons from Financial Economics and Financial Risk Management
Chance, D. M. (2024) · Journal of risk and financial management · doi:10.3390/jrfm17080358 · Cited by 2
COVID 19: Prevention and treatment through the Indian perspective
Chandra, H., Yadav, A., Prasad, R., Sagar, K., Bhardwaj, N., Gupta, K. K., Thakur, G. S., Nigam, M., Pezzani, R., de Lima, J. P. M., et al. (2024) · Cytokine · doi:10.1016/j.cyto.2024.156756 · Cited by 2
Long Non-coding RNAs and CRISPR-Cas Edition in Tumorigenesis
Furtado, C. L. M., Santos, R. D. S., Sales, S. L. A., Teixeira, L. P. R., & Pessoa, C. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-33325-5_3 · Cited by 1
Legislative Architecture and Nudges: Complementary Tools to Increase Legal Order Resilience?
Zorzetto, S. (2022) · Legisprudence library · doi:10.1007/978-3-030-87262-5_11 · Cited by 1
Zeng, Y., Xu, J., Wang, J., Xue, L., Liu, J., Geisler, H. C., Xu, M., Melamed, J. R., Shi, Q., Padilla, M. S., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2525718123 · Cited by 2
Kwolek, E. (2021) · Clinical Ethics · doi:10.1177/14777509211036661 · Cited by 1
“Vaccine trials have shown that multiple candidate vaccines are safe and effective and prioritized vaccine distribution plans have been implemented.(1,2) There are many important ethical considerations with the accelerated development of a vaccine in the context of a global pandemic, and this paper will consider the et…”
BackgroundMueller, B., Padberg, I., Lorke, M., et al. (2025) · medRxiv · doi:10.1101/2025.01.22.25320783 · Cited by 1
Favresse, J., Tré‐Hardy, M., Gillot, C., Cupaiolo, R., Wilmet, A., Beukinga, I., Blairon, L., Bayart, J., Closset, M., Wauthier, L., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e36116 · Cited by 3
“The vaccine efficacy of BNT162b2 and mRNA-1273 was nearly equivalent in phase III trials, respectively 95 % [5] and 94.5 % [6], however this effectiveness and equivalence was questioned [7].”
BackgroundInfluentialMavridis, C., Aidonidis, G., & Kalogeridis, A. (2022) · Qeios · doi:10.32388/h4xgp2.5
Ju, Y.-R., Cho, L.-S., & Lu, C. L. (2025) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbbio.2025.3596771 · Cited by 4
Artificial intelligence in the rational design of lipid nanoparticles for mRNA therapeutics
Zhao, H., Xu, J., Gao, X., Zhu, J., & He, Z. (2026) · The Innovation Drug Discovery · doi:10.59717/j.xinn-drugdisc.2026.100006 · Cited by 6
A Case Series of Myocarditis Related to the COVID-19 Vaccine
Ahmed, H. O., Ahmed, M. M., & Elrasheid, O. (2022) · Cureus · doi:10.7759/cureus.29892 · Cited by 2
“Regarding the COVID-19 vaccine, the results of some trials revealed that the COVID-19 vaccine was effective, safe, and similar to those other vaccines [4].”
ResultAddeo, A., Shah, P., Bordry, N., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-554993/v1 · Cited by 1
Treatment and therapeutic agents
Akhtar, I. N. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824409-8.00002-3 · Cited by 1
Review of advances and future directions in mRNA-based therapeutics for malaria mitigation
Enyi, E. O., & Umeyor, I. C. (2026) · Discover Applied Sciences · doi:10.1007/s42452-026-08662-6 · Cited by 1
“Strong presence in global markets, with multiple approved products like Comirnaty, and Spikevax [49, 52] Table 3 Comparison of pDNA and mRNA vaccines for infectious diseases, with emphasis on malaria mitigation 5 Delivery and administration”
An introduction to RNA therapeutics and their potentials
Bui, N. L., & Chu, D. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.12.020 · Cited by 1
Hashan, M. R., Smoll, N. R., Chapman, G., King, C. L., Walker, J., Kirk, M., Akbar, D., Booy, R., & Khandaker, G. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4181714 · Cited by 1
Ören, M. M., Canbaz, S., Meşe, S., Ağaçfidan, A., Demir, Ö. F., Karaca, E., Doğruyol, A. R., Otcu, G. H., Tükek, T., & Özgülnar, N. (2023) · Vaccines · doi:10.3390/vaccines11050935 · Cited by 1
“On the other hand, the results of clinical studies on the BNT162b2 vaccine showed that the vaccine was 95% effective in preventing symptomatic laboratory-confirmed COVID-19 in individuals with no evidence of a previous SARS-CoV-2 infection [29].”
ResultPan, X., Chen, Y. P., Chen, F. X., He, H., Qi, X. H., & Liang, H. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1820862 · Cited by 1
“The increased odds of an SAE following the second dose (aOR: 1.33) align with the anamnestic immune response, where the “boost” phase triggers more vigorous systemic reactogenicity compared to the initial “prime” dose (36).”
InfluentialGoh, Y. S., Fong, S., Hor, P. X., Amrun, S. N., Lee, C. Y., Young, B. E., Chia, P. Y., Tambyah, P. A., Kalimuddin, S., Pada, S., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1043049 · Cited by 3
“The advent of Spike (S) proteinbased mRNA COVID-19 vaccines has significantly improved the COVID-19 pandemic, with both Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1,273) reporting 95% vaccine efficacy (Polack et al., 2020; Baden et al., 2021).”
BackgroundCorrelates of COVID-19 vaccine uptake among the forcibly displaced: evidence from Libya
Achore, M. (2024) · Archives of Public Health · doi:10.1186/s13690-024-01306-4 · Cited by 1
“COVID-19 vaccines, including Pfizer BioNtech or AstraZeneca (Vaxzevria), are generally robust for treating early strains of COVID-19, effectively reducing hospital admission rates, deaths, and illnesses [6, 32, 45].”
BackgroundTameshkel, F. S., Dargoush, S. A., Amirkalali, B., Javadi, S., Ghiaseddin, A., Alimohamadi, Y., Basi, A., Makiani, M. J., Zamani, F., & Niya, M. H. K. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2022.1095194 · Cited by 1
“The test procedure is as follows: (1) Bring all reagents and specimens to room temperature (18–24C) before beginning the assay.”
BackgroundMethodInfluentialRibeiro, P. D. C., Peixoto, F. M. M. M. C., dos Reis-Neto, E. T., Pileggi, G. S., Bellei, N., Pinheiro, M. M., Magalhães, V. D. O., Biegelmeyer, E., Trolese, A. G. C., de Souza, A. W. S., et al. (2025) · Revista Brasileira de Reumatologia · doi:10.1186/s42358-025-00498-9 · Cited by 2
“S vaccines (Janssen/Johnson & Johnson) have been proven to be safe and to reduce the risk of severe SARS-CoV-2 infection and its complications in the general population [19–23].”
Yıldırım, S., Yılmaz, C., Polat, G., et al. (2023) · Asian Pacific Journal of Tropical Medicine · doi:10.4103/1995-7645.383912 · Cited by 1
Canorio, J., Sánchez, F., & Ramírez-Soto, M. C. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph191811757 · Cited by 1
“Despite patients with obesity showing a reduced immune response to the influenza A (H1N1) vaccine [29], the phase 3 clinical trials of Moderna COVID-19 and PfizerBioNTech COVID-19 vaccines included subgroups of individuals with obesity and severe obesity and showed effective results [28,30,31].”
BackgroundSpatiotemporal distribution of SARS-CoV-2 vaccines and vaccine-related proteins in mice and humans
Heinrich, F., Lücke, J., Zhang, S., Sabihi, M., Bernreuther, C., Giersch, K., Allweiss, L., Hartmann, K., Thies, E., Lange, P., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-47568-6 · Cited by 1
(2022) · doi:10.1101/2022.07.05.22277281 · Cited by 1
“Effective vaccines have been developed 57 and authorized by the FDA to combat this pandemic[10, 11].”
BackgroundA Review Article on Vaccine Development and Therapeutics Approach Against SARS-CoV-2
Yadav, A., Singh, S., Srivastava, V. P., Bardhan, N., Gupta, S., Sarkar, P., & Kaur, H. (2021) · The Open COVID Journal · doi:10.2174/2666958702101010117 · Cited by 1
Four points regarding reproducibility and external statistical validity
Guerin, G. R. (2022) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12498 · Cited by 1
Mechanisms and Strategies for Enhancing DNA Nuclear Entry in Gene Delivery
Sylvers, J., & Yuan, F. (2026) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-026-00927-9 · Cited by 1
Plaxco, A. P., Kmet, J. M., Nolan, V. G., Taylor, M. A., & Smeltzer, M. P. (2022) · AJPM Focus · doi:10.1016/j.focus.2022.100010 · Cited by 2
“have high efficacy against coronavirus disease 2019 (COVID-19) from the original strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).(1,2) Early immunologic and epidemiologic studies suggest that mRNA vaccines provide attenuated protection against the Omicron (B.”
Aoshima, M., & Ohfuji, S. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2147353 · Cited by 1
COVID-19 Vaccination Safety in Patients who have had SARS-CoV-2-induced Chilblains
Poizeau, F., Triquet, L., & Dupuy, A. (2022) · Acta Dermato Venereologica · doi:10.2340/actadv.v102.888 · Cited by 1
“Regarding the Pfizer/ BioNTech vaccine, individuals who had developed SARSCoV-2-induced chilblains had similar reactogenicity to the participants aged 16–55 years in the vaccine trial (Table I) (13).”
BackgroundMontoya, M. A., & Hernández‐Adame, L. (2022) · Mundo Nano Revista Interdisciplinaria en Nanociencia y Nanotecnología · doi:10.22201/ceiich.24485691e.2023.30.69683 · Cited by 1
Patalon, T., Moshe, S. B., Peretz, A., Neuberger, A., Schreiber, L., Lazar, R., Supino‐Rosin, L., Perez, G., Mizrahi-Reuveni, M., & Gazit, S. (2022) · Eurosurveillance · doi:10.2807/1560-7917.es.2022.27.40.2100703 · Cited by 1
Vaccines and autoimmunity during the COVID-19 pandemic
Velikova, T. V. (2022) · World Journal of Immunology · doi:10.5411/wji.v12.i2.9 · Cited by 1
COVID-19 and orthodontic treatment: current perspectives
Mote, N., Mani, S., Pallan, K., et al. (2021) · Dental Press Journal of Orthodontics · doi:10.1590/2177-6709.26.3.e21ins3 · Cited by 1
The effect of RNA and non-RNA vaccines in variants of Covid-19: A narrative review
Rahmannia, M., Firouzabadi, S. R., Hasani, A. H. S., Khanali, F., Vosoughian, F., Mirzaei, R., & Esmaeili, H. (2021) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs211572112 · Cited by 1
Jensen, C. B., Sørensen, A. S., Hansen, K. T., Hansen, S. N., Josiasen, M., Marc, A. H. L., Gram, S. A., Fahnøe, C. L., Nielsen, H., Rask, C. U., et al. (2026) · Public Health · doi:10.1016/j.puhe.2026.106429 · Cited by 1
Assessment of the BNT162B2 COVID-19 vaccine immune response in Brazilian indigenous adolescents
de Oliveira, L. A., de Morais, I. R. B., Marchioro, S. B., de Almeida, G. B., de Souza, G. H. D. A., Ferreira, T. D. S., Rossoni, R., Barbosa, D. D. O., Navarini, V. J., Croda, J., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126494 · Cited by 1
mRNA-delivered neutralizing antibodies confer protection against SARS-CoV-2 in animal models
Hazell, N. C., Reyna, R. A., Adam, A., Bonam, S. R., Bei, J., Kumar, N., Nguyen, T., Plante, J. A., Wu, T., Walker, D. H., et al. (2026) · Journal of Virology · doi:10.1128/jvi.01897-25 · Cited by 5
“The clinical approval and widespread use of two mRNA-based COVID-19 vaccines marked a major milestone in the successful translation of this technology (27, 28).”
Asano, K., Fujisawa, T., Nakamura, Y., Nagata, M., Hide, M., & Fujieda, S. (2021) · PubMed · doi:10.15036/arerugi.70.215 · Cited by 1
Lu-Culligan, A., Tabachnikova, A., Tokuyama, M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.07.471539 · Cited by 1
Gebski, V., Silva, S. S. M., Byth, K., Jenkins, A. J., & KEECH, A. C. (2023) · Bioinformatics Advances · doi:10.1093/bioadv/vbad148 · Cited by 2
Liu, H., Mehdi, M. M., Jiang, L., Liu, Y., Ma, Y., Teng, Z., Bing, L., Guo, H., & Sun, S. (2026) · Virology Journal · doi:10.1186/s12985-025-03059-0 · Cited by 3
“The success of mRNA vaccines against COVID-19, achieving protection efficacies exceeding 95% [9, 10], represents a key milestone in the vaccine industry.”
Gonçalves, B. P., Hall, M. D., Jassat, W., Balan, V., Murthy, S., Kartsonaki, C., Semple, M. G., Rojek, A. M., Baruch, J., Reyes, L. F., et al. (2022) · medRxiv · doi:10.1101/2022.06.22.22276764 · Cited by 1
Oberemok, V. V., Andreeva, O. A., Laikova, K. V., Novikov, I. A., Puzanova, Y. V., & Kubyshkin, A. V. (2022) · Inflammation Research · doi:10.1007/s00011-022-01567-1 · Cited by 1
Guo, C., Sachithanandham, J., Zhong, W., Craney, M. C., Villano, J., Pekosz, A. S., & Gould, S. J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.04.574272 · Cited by 1
Pehlivan, Ö., & Gezer, H. H. (2022) · Journal of Surgery and Medicine · doi:10.28982/josam.7339 · Cited by 1
Intawong, K., Chariyalertsak, S., Chalom, K., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1973470/v1 · Cited by 1
The most dangerous drugs ever unleashed on the human population in the history of medicinePreprint
Godwin, B. (2022) · doi:10.31237/osf.io/pd3cj · Cited by 1
Behrens, C., Samii-Moghadam, M., Gasperazzo, T., Gross, A. M., Mitchell, J., & Lampe, J. B. (2021) · medRxiv · doi:10.1101/2021.12.15.21267847 · Cited by 1
Lipid nanoparticles loaded with anticancer bioactives: state of the art
Faria, G. N. F., Bhavsar, D., Munshi, A., & Ramesh, R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15401-0.00017-8 · Cited by 2
Briones‐Claudett, K. H., Briones-Claudett, M. H., Vásconez, R. A. M., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1409323 · Cited by 1
Checo, M., & Brache, V. (2022) · Ciencia y Salud · doi:10.22206/cysa.2022.v6i2.pp103-109 · Cited by 1
Brugha, R. E., Kirkham, A. J., Bate, J. M., Burke, G. A. A., Hughes, A. I., Magwaro, S., Pope, A., Beesley, R. P., Lax, S., Kelly, E., et al. (2025) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2025.114873 · Cited by 2
Thoo, L., Gumowski, P. I., Kammermann, K., Nussli, S., Grabscheid, B., Hausmann, O. V., Axius, U., Pichler, W. J., & Yerly, D. (2021) · Swiss Medical Weekly · doi:10.4414/smw.2021.w30005 · Cited by 1
Ben-Aharon, O., Sergienko, R., Iskrov, G. G., & Greenberg, D. (2024) · Israel Journal of Health Policy Research · doi:10.1186/s13584-024-00594-z · Cited by 1
“The COVID-19 vaccination campaigns based on mRNA technology demonstrated high levels of safety and efficacy/effectiveness in both clinical trials [4, 5] and real-world settings in many countries [6, 7].”
BackgroundKipourgos, G., Kourtis, G., Papatheodorou, M., Elesnitsalis, G., Filtiseniou, P., Albani, E. N., & Tzenalis, A. (2022) · Nursing Forum · doi:10.1111/nuf.12791 · Cited by 1
Serological response to vaccines against SARS-CoV-2 in patients with inflammatory bowel disease
Algaba, A., Romero, S., Granja, A., Garza, D., Aller, M. D. M., Barrero, S., Guerra, I., Gil, M., Pizarro, N., Ruiz, P., et al. (2023) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2022.05.001 · Cited by 1
Shareef, U. M. M. A., Kumar, V., & Kamath, V. (2021) · APIK Journal of Internal Medicine · doi:10.4103/ajim.ajim_63_20 · Cited by 3
Zacks, N., Bar‐Shai, A., Levi, H., Breslavsky, A., Maayan, S. L., Tsyba, E., Feitelovich, S., Wand, O., Schaffer, M., Sherer, Y., et al. (2022) · Vaccines · doi:10.3390/vaccines10091443 · Cited by 2
“The phase‐3 study of BNT162b2 validated the efficacy and safety of the vaccine: two doses of BNT162b2 provided 95% protection against COVID‐19 in persons 16 years and older, and the safety was similar to other viral vaccines over an average of twomonths [14].”
BackgroundCOVID-19 vaccines and pregnancy (literature review)
Adamyan, L. V., Filippov, O. S., Stepanian, A. A., Aznaurova, Y. B., & Владимировна, К. О. (2021) · Russian Journal of Human Reproduction · doi:10.17116/repro2021270325 · Cited by 2
The persistence of COVID-19 vaccine artifacts in bodily fluids and tissues: a systematic review
Selem, E., Raszek, M., Varón, J., & Halma, M. T. J. (2026) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-026-00939-2 · Cited by 3
“After the initial clinical trials for the Pfizer and Mod-erna vaccines [19, 20], they were soon granted emergency use authorization (EUA) in the United States [21], as well as the respective authorization in countries across the globe.”
RNAs in the diagnosis and treatment of major diseases
Huang, D., Zhang, T., Jiang, X., Li, J., Yan, Z., Sun, R., Su, S., & Hong, W. (2024) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2024-0523 · Cited by 1
How Losing Sleep Following Vaccination May Weaken the Response to SARS-CoV Vaccines
Akhtar, N., Srivastava, R. K., & Shrivastava, D. K. (2022) · Sleep and Vigilance · doi:10.1007/s41782-022-00195-3 · Cited by 1
“6% for SARS-CoV-2 vaccine efficacy after the second dose [1].”
BackgroundMavridis, C., Aidonidis, G., & Kalogeridis, A. (2022) · Qeios · doi:10.32388/h4xgp2.7
Dimeglio, C. (2025) · Vaccines · doi:10.3390/vaccines13121251 · Cited by 1
“The global response to SARS-CoV-2 has advanced at unprecedented speed: vaccines developed in record time, mass immunization campaigns, and real-world data confirming reductions in severe disease and death [1,2].”
Caraco, Y., Madar-Balakirski, N., Ben‐Ami, E., Zeltser, D., Maayan, S. L., Eliakim‐Raz, N., Peer, A., Brosh‐Nissimov, T., Vishlitzky, V., Beth-Din, A., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127837 · Cited by 1
Robust two-dose vaccination schemes and the directed b -matching problem
Segschneider, J., & Koster, A. M. C. A. (2024) · Discrete Applied Mathematics · doi:10.1016/j.dam.2024.06.029 · Cited by 1
Team science and building a team
Chowdhry, V. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88423-5.00055-8 · Cited by 1
Snapshot data-driven covariance steering for linear dynamical systems
Inoue, Y., Inoue, M., Kashima, K., & Onogi, Y. (2025) · Nonlinear Theory and Its Applications IEICE · doi:10.1587/nolta.17.138 · Cited by 1
Evaluation of the Therapy Protocols and Vaccines Applied in the COVID-19 Pandemic
Özbey, G., Hanafiah, A., Sukri, A., Zigo, F., & Arvaiová, J. (2023) · Emerging Science Journal · doi:10.28991/esj-2023-07-05-022 · Cited by 1
“To prevent the COVID-19 infection, which contributes to a high economic and medical burden, a safe and effective prophylactic vaccine is urgently needed [6].”
BackgroundDillman, R. O., Nistor, G. I., & Keirstead, H. S. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2588861 · Cited by 1
Proteomic characteristics of the treatment trajectory of patients with COVID-19
Li, X., Ding, G., Li, S., Liu, C., Zheng, X., Luo, J., He, S., Zeng, F., Huang, X., & Zeng, F. (2024) · Archives of Virology · doi:10.1007/s00705-024-05991-y · Cited by 3
Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccinationPreprint
Zhou, R., Wang, P., Wong, Y.-C., Xu, H., Lau, S.-Y., Liu, L., Mok, B. W.-Y., Peng, Q., Liu, N., Woo, K. F., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.21.465252 · Cited by 1
The historical background of personalized medicine
Guillén, D. G. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780198863465.003.0002 · Cited by 2
Müller, M., Volzke, J., Subin, B., et al. (2021) · medRxiv · doi:10.1101/2021.09.17.21263726 · Cited by 2
Şahin, M. K., Aker, S., Şahin, G., & Böke, Ö. (2024) · Konuralp Tıp Dergisi · doi:10.18521/ktd.1319749 · Cited by 2
Association between physical activity status and severity of COVID-19 in older adults
Tsuzuki, S., Akiyama, T., Matsunaga, N., & Ohmagari, N. (2022) · Epidemiology and Infection · doi:10.1017/s0950268822001686 · Cited by 2
“At least two vaccine doses is strongly associated with non-severe illness for the Omicron VOC, as well as for other strains Shinya Tsuzuki et al. [13, 30 – 32].”
BackgroundAn Analytic Look at the Last Pandemic’s Spread and Its Control by Decision-Makers
VILCHES, T. N., Rubio, F. A., de Almeida, G. B., & Ferreira, C. P. (2024) · Modeling and simulation in science, engineering & technology · doi:10.1007/978-3-031-56794-0_5 · Cited by 1
Nguyen, V. G., Yavlinsky, A., Beale, S., Hoskins, S., Lampos, V., Braithwaite, I., Byrne, T., Fong, W. L. E., Fragaszy, E., Geismar, C., et al. (2021) · medRxiv · doi:10.1101/2021.12.21.21268214 · Cited by 1
“Phase-III randomised controlled trials (RCTs) have demonstrated that the BNT162b2 and ChAdOx1 vaccines are safe and have good efficacy against symptomatic and severe disease (1,2).”
BackgroundLababidi, G. H., Lababidi, H., Bitar, F. F., & Arabi, M. T. (2024) · Cardiology in the Young · doi:10.1017/s1047951124026118 · Cited by 1
SARS-CoV-2, COVID-19, and Children: Myths and Evidence
Joffe, A. R. (2023) · Springer eBooks · doi:10.1007/978-3-031-41542-5_20 · Cited by 1
Direct pulmonary delivery route in lung cancer: a highway for siRNA therapeutics
Sharif, M. S., Luzzi, L., Laurentiis, M. D., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1722906 · Cited by 1
The Half-Life of a Mark: Dwell Time and the Missing Time Axis of the Epitranscriptome
Tani, H. (2026) · Journal of Molecular Biology · doi:10.1016/j.jmb.2026.169944 · Cited by 1
Precision cardiology: Integrating gene therapy, genome editing, and single-cell genomics
Nishino, T., & Ono, K. (2025) · Journal of Cardiology · doi:10.1016/j.jjcc.2025.09.009 · Cited by 3
Zhou, Y., Gao, W., Huang, X., Yan, Y., Wu, S., Shan, X., Chen, S., Qiu, M., Ma, G., & Xia, Y. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102667 · Cited by 2
In-vivo Delivery of mRNA-Based Vaccines and Administration Routes
Gümral, R. (2021) · Journal of Molecular Virology and Immunology · doi:10.46683/jmvi.2020.16 · Cited by 1
Ohkubo, Y., Ohmura, S., Ishihara, R., & Miyamoto, T. (2022) · Case Reports in Rheumatology · doi:10.1155/2022/3124887 · Cited by 1
“Although minor adverse reactions are common, few serious adverse reactions have been reported [1, 2].”
BackgroundArrospide, A., Sagardui, M. G., Larizgoitia, I., Iturralde, A., Moreda, A. B., & Mar, J. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.05.061 · Cited by 2
“Nonetheless, the clinical trials undertaken before the approval of these vaccines did not provide data on the duration of the immunity acquired after full vaccination [2,3].”
Huang, D. P., Chen, C., Xuan, W., Pan, S., Fu, Z., Chen, J., Li, W., Jiang, X., Zhao, H., Zhou, X., et al. (2023) · Anesthesiology and Perioperative Science · doi:10.1007/s44254-023-00038-y · Cited by 2
Elvira, R., Guan, J. S., Mu, Y., Tan, E., & Zhou, Z. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118802 · Cited by 3
Suzanna, S., Dekawaty, A., & Haryoko, I. (2023) · Masker Medika · doi:10.52523/maskermedika.v11i1.522
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.